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Introduction
Neoplasms originating in the anterior mediastinum usually 
include thymoma comprising thymic carcinoma, germ cell 
tumors, lymphoma, and metastatic tumors (1). More than 
80% of patients with advanced mediastinal malignancies 
present with symptoms that may be due to compression or 
direct invasion of the neighboring structures or that may 
be related to paraneoplastic syndromes. Some of these 
tumors, because of their aggressive behavior, may extend to 
adjacent organs; further technical issues may be addressed 
concerning the resection and the choice of the surgical 
approach (2,3).
In the presence of invasive masses of the anterior 
mediastinum, surgery can be indicated for radical resection, 
more frequently as a part of a multimodality treatment; 
a curative surgical resection sometimes cannot be 
accomplished because anterior mediastinal tumor (usually 
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not symptomatic in the early stages) at the time of diagnosis 
already invade extensively the surrounding organs, including 
major blood vessels, lung parenchyma and pericardium (3).
Because of related morbidity and mortality and limited 
experience available on the prognostic advantage for 
long term, usually in the past, surgical resections of large 
masses along with the neighboring structures were not 
offered to patients. Nevertheless, advances in surgical 
technique and perioperative management obtained in the 
last decades, as well as increased oncologic experience 
in this field, have allowed radical exeresis of invasive 
tumors requiring resections extended to the surrounding 
structures and complex vascular reconstructions in 
selected patients (4-6). Such aggressive surgical treatment 
has been proposed in association or not with adjuvant 
chemo- or radiotherapy regimens, achieving encouraging 
oncologic results with limited morbidity and mortality in 
experienced surgical institution (7-9). Moreover, some of 
these patients present with immediately life-threatening 
problems such as congestive heart failure or impending 
cardiovascular collapse due to the large mass compression. 
An aggressive surgical treatment may remain the only 
option, especially for chemoresistant germ-cell tumors, 
since medical palliation is usually ineffective in this setting. 
Thus, salvage surgery is offered in selected patients with 
advanced mediastinal tumors, results from few limited series 
have been reported; fewer reviews on this topic have been 
published. We hereby present the most recent relevant 
experiences about this. 
Superior vena cava (SVC)
The resection and reconstruction of the SVC is more 
frequently required when anterior mediastinal tumors that 
infiltrate the surrounding vascular structures are amenable 
for radical en bloc exeresis 
A partial SVC resection and vascular repair either by 
direct suture or by interposition of a patch, usually of 
biologic material (pericardium), can be accomplished if 
the vessel circumference is infiltrated for less than 30%. A 
complete resection of the vessel with prosthetic replacement 
is required if a larger circumferential involvement is present. 
SVC resection and reconstruction represent a major 
technical challenge, especially for the potential negative 
effect of clamping a patent vessel (10); a partial caval 
clamping or clamping of chronically obstructed SVC is 
usually well tolerated, while a complete clamping of a patent 
SVC could lead to a marked hemodynamic imbalance.
A SVC conduit replacement can be performed if the 
confluence of both the innominate veins is not infiltrated. 
After clamping and vascular resection, the anastomosis 
between the superior caval stump and the prosthetic 
conduit is performed first with 5-0 polypropylene suture. 
In order to avoid the kinking of the conduit, the length 
of the prosthesis must be meticulously adapted so that 
the distal anastomosis could be under tension. When 
the junction between the origin of the SVC and the 
confluence with the innominate veins is infiltrated by the 
tumour, the revascularization is usually performed between 
the left innominate vein and the inferior SVC stump (or 
the right atrium) with closure of the right innominate 
vein, or alternatively between the right innominate vein 
and the inferior SVC stump (or the right atrium) with 
closure of the left innominate vein, according to the local 
invasion. Reconstruction from the right innominate vein 
usually provide a lower risk of prosthetic kinking; in fact, 
the residual venous stump is shorter and the direction 
of the graft is almost vertical. Some authors report the 
revascularization of both the innominate veins implanted 
independently at the right atrium. The current author 
believes that it should be avoided because the blood flow 
through the graft is too low and exposes at high risk of 
thrombosis. Total resections of the SVC and both the 
innominate veins and reconstruction with a Y-shaped 
synthetic prosthesis (Dacron or PTFE) have been 
successfully realized and reported in literature (11).
Aorta and epiaortic vessels
Some large mediastinal masses on the left side can infiltrate 
the arch or the descending aorta, while some other tumors 
can infiltrate the ascending aorta, carotid (Figures 1-3) and 
subclavian artery from the super anterior mediastinum. 
Sometimes, large tumors even with radiologically extensive 
aortic involvement present intraoperatively with a limited 
aortic adventitia infiltration that requires eventually cross-
clamping but certainly not cardiopulmonary bypass (CPB) 
for resection. Otherwise, CPB allows safe resection when, 
in selected cases, a conduit reconstruction is required (12) 
(Figure 1B, Figure 3B,C) Dacron is generally preferred 
among materials for reconstruction for stiffness and 
resistance at high-pressure blood flow. 
Materials for vascular reconstruction
Various biologic (autologous or heterologous) or 
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synthetic materials have been proposed for these vascular 
reconstructions.
For reconstruction of low-pressure thoracic vessels, 
biologic materials ,  such as  autologous or bovine 
pericardium, saphenous vein and azygos vein have gained 
large acceptance because of improved biocompatibility, 
lower risk of infection and thrombosis, and lower costs than 
synthetic materials (13-15).
Among the biologic materials, the bovine pericardium is 
currently the most used option. Its characteristics, such as 
stiff edges and the limited tendency to retract, facilitating 
its adaptation and suturing to the vascular wall, are an 
advantage. However, in the patch reconstructive procedures 
it has lower diffusion with respect to the autologous 
pericardium because of inferior biocompatibility and 
higher costs (16). Conversely, when total SVC replacement 
is required, bovine pericardium is preferred because the 
autologous tissue is generally not sufficient to create a long 
conduit. The pericardial conduit that has lower risk of 
thrombosis than synthetic materials does not necessitate 
long-term anticoagulation (15,17). The current authors 
presented an original technique for the intraoperative 
construction of a heterologous pericardial conduit to be 
used for SVC replacement (18).
Autologous venous grafts (i.e., saphenous) have a limited 
diameter that is sufficient only for the reconstruction 
of the brachiocephalic vein and is not suitable for SVC 
replacement. Saphenous vein graft of adequate diameter has 
been created by suturing the venous wall in a spiral fashion 
around a stent or a chest tube of appropriate size (13). 
Among the synthetic materials employed for graft 
reconstruction of the SVC (Dacron, PTFE, Gore-tex), the 
PTFE is the option of choice. It is the synthetic material 
showing the highest patency rate at long term and, shortly 
after its implantation, it becomes re-epithelialized with 
autogenous epithelial cells in humans (11,19). PTFE 
grafts (that are usually reinforced with external rings) 
have low risk of infection, less platelet deposition, and 
less thrombogenicity of the flow surface if compared with 
Dacron grafts. 
For high-pressure vessels reconstruction such as aorta or 
carotid and subclavian artery, the risk of thrombosis is lower 
than in case of SVC reconstruction. In these conditions, 
the main issue that should be addressed is to obtain an 
adequate resistance of the reconstructed portion at the 
high-pressure flow. Available autologous or heterologous 
biologic materials (with exception of cadaveric graft) are 
not sufficiently responding to this requirement. Therefore, 
synthetic materials for vascular reconstruction are preferred. 
The current author believes that, among synthetic materials, 
the polyester such as Dacron are the suitable choice for 
Figure 1 Anterior mediastinal mass infiltrating the aorta. (A) 
CT scan image illustrating extensive infiltration of the vessel; (B) 
intraoperative picture: the tumor has been resected and an aorta 
Dacron conduit reconstruction has been performed. 
A
B
Figure 2 CT scan image showing anterior mediastinal tumor 
invading the carotid artery. 
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aorta and epiaortic trunks prosthetic replacement. 
Carina
Carinal resection for direct infiltration of an advanced 
mediastinal tumor is definitely even rarer than mediastinal 
great vessels resection. Carina is generally infiltrated by 
primary or recurrent neoplasms like lymphoma or germ-
cell tumor (Figure 4). In this condition, where the carina is 
generally involved in the midline, the surgical approaches 
that should be preferred are median sternotomy or clamshell 
incision. These approaches provide wide exposure of the 
surgical field and facilitate the resection and reconstruction 
of the carina especially when the tumor extends towards the 
left side (Figure 4B).
Some authors suggest the use of CPB/ECMO instead 
of cross-field ventilation with the aim to simplify the 
reconstruction phase and to improve results of surgery 
reducing the operative time (20,21). The current authors’ 
choice is for the cross-field ventilation, due to the potential 
increase of morbidity related to CPB/ECMO (4,17). 
Airway reconstruction is performed with absorbable 
material, and we suggest the use of 3-0 monofilament (PDS) 
in an interrupted-sutures fashion to facilitate the adjustment 
of caliber discrepancy between the tracheal/bronchial 
stumps (22) (Figure 4B,C).
Figure 3 Intraoperative picture showing a carotid artery prosthesis reconstruction for anterior superior mediastinal tumor. (A) Carotid 
artery is infiltrated by the super anterior mediastinal tumor; (B) the tumor has been resected en-bloc with carotid artery circumferential 
portion; (C) reconstructed carotid artery (dacron).
A B C
Figure 4 Recurrence of teratoma infiltrating the carina. (A) CT scan image; (B) median sternotomy had been performed and mediastinum 
is exposed; (C) left carina resection has been performed; stiches between trachea and right main bronchus are in place but still untied; (D) 
trachea-bronchial reconstruction is complete. 
A B C D
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Anyway, the reports of these carinal reconstructive 
operations for resection of mediastinal tumors are quite 
anecdotal. 
Comments
The surgical treatment of locally advanced mediastinal 
tumors invading the great vessels and other nearby 
structures still represent a tricky question, principally due 
to the technical complexity of the resective phase, the 
contingent need to carry out viable vascular reconstructions 
and, therefore, the proper management of pathophysiologic 
issues. 
New technologies as 3D reconstruction or printing 
can be fascinating and useful for planning the operation, 
nevertheless these technologies even helpful are not 
conclusive and only intraoperative findings are reliable to 
establish the real infiltration of the organs; this even more 
true after neoadjuvant chemotherapy, when the scar tissue 
could be indistinguishable from neoplastic residual tissue.
Published large-number series providing oncologic 
outcomes of patients who have undergone extended radical 
surgery for invasive mediastinal masses are just a few 
(5,7,8,11,23-25). Furthermore, the wide variety of different 
histologies included in some of these studies (5,7,11,23), as 
well as the heterogeneity of chemo and radiation therapies 
employed (7,8), did not allow for the development of clear 
oncologic guidelines. 
On the other hand, the implementation over time of 
the oncologic treatments that now include immunotherapy 
could represent a great chance for patients with advanced 
mediastinal tumours. Novel oncologic regimens may reduce 
the neoplastic tissue increasing the rate of patients receiving 
an “adjuvant” R0 resection. However, when considering 
patients affected by advanced mediastinal tumours that 
involve the surrounding vascular structures with immediate 
life-treating problems due to the invasion or compression of 
the vessel, surgery should be taken into account as first-line 
treatment. 
Bacha et al. (7), reported results from the Marie 
Lannelongue Hospital long-term experience of surgical 
resection of invasive primary mediastinal neoplasms. They 
included a total of 89 patients with different pathologic 
diagnosis: advanced thymoma (n=35), thymic carcinoma 
(n=12), germ cell tumors (n=17), lymphomas (n=16), 
neurogenic tumors (n=3), thyroid carcinoma (n=3), radiation 
induced sarcomas (n=2), and mediastinal mesothelioma 
(n=1). Seventy-four percent of these patients had a tumor 
located in the anterior mediastinum, so sternotomy was the 
preferred approach. In three cases of chemoresistant germ 
cell masses a clamshell incision was required. Concerning 
the surrounding infiltrated organs, pericardium was 
resected in most cases (73%). A concurrent pulmonary 
resection was required in 55% of patients; among these, 28 
wedge resections, 16 lobectomies and 5 pneumonectomies. 
Impairment of the major vascular structures was reported 
in 40% of cases, including 21 SVC and 13 brachiocephalic 
veins involvement. In all cases of SVC resection, vascular 
reconstruction was performed by using a synthetic conduit 
(PTFE). Instead, patients in whom the infiltration was 
limited to a single innominate branch didn’t require any 
vascular replacement. Complete removal of the tumor 
(R0) was achieved in 79% of cases. Major complications 
occurred in 17% of patients, requiring reoperation in 
4 cases (4.5%). Operative mortality was 6%. In patients 
who have undergone SVC replacement, the patency of the 
PTFE conduit at 3 months was preserved in all the cases 
except for one. One more graft occlusion was reported after 
15 months in a patient who had inserted a central venous 
catheter. About the oncologic cares, adjuvant radiation 
treatments were administered in 85% of thymomas and 
in 58% of thymic carcinomas, while 67% of patients with 
a diagnosis of thymic carcinoma received postoperative 
chemotherapy. Fourteen of the patients with germ cell 
carcinoma (82%) underwent cisplatin-based chemotherapy 
regimen in the preoperative period; ten of these even 
received postoperative chemotherapy. Eight patients 
who had a preoperative diagnosis of lymphoma received 
chemotherapy followed by removal of the residual tumor. 
When the diagnosis of lymphoma was achieved under the 
operation, postoperative chemotherapy was administered. 
Five-year overall survival rate was 63%. When considering 
survival related to histology, it was 69% for thymomas (stage 
III + IV), 42% for thymic carcinomas, 48% for patients with 
a germ cell tumor and 83% for those with lymphoma at 
5-year. Recurrence rate was higher in the thymic carcinoma 
group (75% at 5-year).
A paper from Chen and colleagues (26) focused on 
the surgical management of complex malignant anterior 
mediastinal tumors invading the SVC-innominate 
veins system. A total of 15 patients with heterogeneous 
histologies were enrolled, including 9 malignant thymomas 
and one case of each between thymic carcinoma, teratoma, 
embryonal carcinoma, Hodgkin’s lymphoma, non-
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Hodgkin’s lymphoma and mixed teratoma with thymoma. 
A median sternotomy was performed in all patients. In the 
event of limited invasion of the SVC or a brachio-cephalic 
vein, non-circumferential resection of the vascular wall was 
accomplished by a partial clamping of the vessel and then 
repaired through a running suture (n=7). Three further cases 
required the tailoring of a pericardial patch to repair the 
vascular defect; a complete caval clamping was performed 
in all of these patients. Rest of the patients underwent 
the complete resection of the SVC and both the brachio-
cephalic veins at the confluence (n=3). Reconstruction 
was performed in 2 cases by the interposition of a Dacron 
conduit between the right innominate vein and the right 
atrium (with ligature of the left innominate), and by the 
use of a “Y” shaped Dacron graft in one case. Two patients 
in whom the vascular involvement was limited to the left 
brachio-cephalic vein, underwent the tumor resection 
and ligature of vein stumps without need for a vascular 
reconstruction. Major complication rate was 13%. No 
perioperative mortality was observed. Four patients (26%) 
received chemotherapy before surgery. At a median follow-
up of 35-month all patients were alive except for one. Upon 
publication, disease-free survival ranged between 10 and 43 
months.
Over the past few years, some attractive series proposed 
the use of CPB in the surgical treatment of anterior and 
middle mediastinum neoplasms, most of them invading 
the heart or major vessels, with the aim to secure the 
complex removal of locally advanced masses or to allow safe 
manipulation of the tumor during resection (4,27-29). On 
the subject, a study published in 2002 (4), retrospectively 
reviewed results of 19 patients with thoraco-mediastinal 
malignancies involving the heart or great vessels, or 
resulting in substantial cardiac compression, who had 
undergone resection under CPB at The University of 
Texas M.D. Anderson Cancer Center. Only 20% among 
the 19 cases had a diagnosis of primary mediastinal 
neoplasm. Median sternotomy and clamshell incision 
were the preferred approaches (68% and 15% of cases 
respectively). After resection of the tumor, over half of the 
patients had no need for any vascular reconstruction other 
than direct suture of the defect. The remaining patients 
(42%) required different kinds of reconstruction by the 
use of autologous and heterologous pericardial tissues or 
synthetic prosthesis, such as Dacron conduits and Gore-
tex patches. Overall/whole morbidity rate was 58%, instead 
perioperative mortality was 11%. Radical resection (R0) 
of the tumor was achieved in 79% of cases. Median overall 
survival was 62.4±25.4 months. In general, overall survival 
was significantly improved in those patients who have 
undergone an R0 resection. On the same topic, in 2004 
Park et al. published the experience from the Memorial 
Sloan-Kettering Cancer Center (23). Ten patients with 
different histotype of neoplasms invading great vessels or 
part of the cardiac chambers were included in this study. 
In 7 cases CPB was employed. Three patients had a tumor 
from the anterior mediastinum causing SVC obstruction, 
including one from each of advanced thymoma, malignant 
teratoma and synovial cell sarcoma. The stage IV thymoma 
required a hemi-clamshell approach, while sternotomy 
was used in the other two patients. SVC replacement was 
performed through the use of a ringed Gore-tex prosthesis. 
With regard to these three operations, CPB was required 
only in the one for teratoma. No perioperative mortality 
was recorded. No postoperative oncologic treatments were 
administered in the anterior mediastinum subset of patients, 
nevertheless, the one with malignant teratoma received 
neoadjuvant chemotherapy before surgery. Despite the 
non-complete (R1) resection margins, both patients with 
malignant teratoma and synovial sarcoma were still alive 
at the time of publication and after a follow-up period of 
33 months and 69 months respectively. By contrast, the 
patient with thymoma who has accomplished an R0 excision 
of the tumor, died of disease after 29 months due to brain 
metastasis progression. Although the patient with thymoma 
received a radical (R0) resection, he died due to brain 
relapse of the disease after 29 months.
If you look only at patients with Masaoka stage III and 
IV thymic malignancies, one of the most powerful variables 
affecting prognosis is the achievement of a radical resection 
(8,30,31). Surgical debulking or incomplete resections 
(R1, R2) usually do not modify long-term outcomes (32). 
Nevertheless, due to the very extensive involvement of 
nearby structures, radical surgery for invasive thymic masses 
may not be praticable in 30% for 40% of cases. The largest 
published surgical experience from the Massachusetts 
General Hospital (30), which included 179 patients 
with epithelial thymic tumors, showed a higher rate of 
recurrence in patients with Masaoka stage III–IV tumors 
than in all other patients (stage III: 31%, stage IV: 45% vs. 
other stages: 2%).
In 2003, the present authors reported results of a 
multimodality approach of treatment in 45 stage III thymic 
tumors, including 11 patients with a diagnosis of thymic 
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carcinoma (8). Patients presenting with SVC involvement, 
pericardial invasion or limited infiltration of the lung 
and mediastinal pleura (66.6%; n=30) were considered 
eligible and then were included for primary surgery. All 
the other patients (33.4%; n=15), whose tumors were 
considered not completely resectable due to the extensive 
invasion of the surrounding organs, received induction 
chemotherapy followed by resection of the residual tumor. 
Median sternotomy was the approach of choice in all cases. 
When a radical tumor resection was achieved, adjuvant 
chemotherapy and 40 Gy dosage of radiotherapy were 
administered in the postoperative period, whereas in case 
of incomplete resection the radiation dose was increased 
at 50 to 60 Gy. Eleven patients underwent vascular 
reconstruction through a bovine pericardial conduit 
interposition: in 9 cases, it was completed after resection of 
the SVC, in the remaining two cases, it followed resection 
of the left innominate vein. Radical resection was achieved 
in 82% of thymic carcinomas, whereas in patients with 
other histologies the R0 resection rate was 91%. Major 
complications occurred in 6.7% of cases. No operative 
mortality was observed. Ten-year overall actuarial survival 
rate was 78%, while the cumulative disease-free survival 
rate was 53%. Considering patients who had undergone 
a complete resection, 10-year survival rate was 80%, 
compared with 60% for patients with R1–R2 resections. In 
the group of patients receiving preoperative chemotherapy, 
10-year survival rate was 90%, although it was 71% for 
patients undergoing primary surgery.
Our recent homogenous case series (25) including only 
patients undergoing SVC conduit replacement for thymoma 
or thymic carcinoma (n=27; 21 thymoma, 6 thymic 
carcinoma) reports results after vascular reconstruction 
always performed by the cross-clamping technique. Twelve 
patients had undergone previous oncology treatment. 
Vascular reconstruction was synthetic (PTFE) in 13 cases in 
the first study period and biological (n=14) more recently; 
with a 100% long-term patency after pericardial conduit 
reconstruction. Mortality and major complication rates 
were 7.4% and 11.1%, respectively. Long-term patency 
of Cumulative 3- and 5-year cancer-specific survival of 
both thymoma and thymic carcinoma patients (including 5 
associated pneumonectomy) were 90.5% and 75.4%. 
Petrella and colleagues (33) reported results from a series 
of 21 patients that, up to 2005, had undergone salvage 
resection of mediastinal tumors with different histologies 
including thymoma (n=8) and thymic carcinoma (n=3), 
synovial sarcoma, neuroendocrine mediastinal tumor, 
teratoblastoma, dysgerminoma, thyroid carcinoma and 
Hodgkin lymphoma. All the patients underwent surgery for 
persistent or recurrent tumor after previous local treatment 
with curative intent or exclusive chemotherapy for bulky 
tumor.
Extended vascular resection was required in 10 cases 
and in 1 under CBP. They reported mortality rate of 4.7% 
and a morbidity rate of 19%. At median follow-up of 
30.6 months, cumulative survival that included all the 
histology types showed a 5-year survival of 56.6%; 
prognosis was better for thymic malignancies than for other 
(mediastinal tumor) histology (5-year survival: 87.5% vs. 
26.7%). In conclusion, mediastinal salvage surgery should 
be taken into account as therapeutic option in selected cases 
because of good -short and long-term results.
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